The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients.
Through the partnership, the two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions.
This will allow the integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring and the latest research outcomes. This comprehensive information is intended to support clinicians in providing the right treatment and quality of care for their patients.
For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease.
Meanwhile in the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they occur.
“This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” said CEO of Roche Diagnostics, Roland Diggelmann.
“This is the first time that two major players in healthcare have combined digital, in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry,” concluded President and CEO of GE Healthcare, Kieran Murphy.